Altai Capital Pushes OraSure for Sale, Seeks Board Seats

Activist Investor Targets OraSure Technologies

Activist investor Altai Capital Management is publicly pressuring medical device maker OraSure Technologies to explore a sale. The hedge fund, which holds an approximate 5% stake, is also seeking two board seats to oversee a strategic review process, escalating its campaign after private talks failed.

Situational Overview

Altai's push follows a significant 73% decline in OraSure's stock price over the last five years, driven by diminishing demand for its COVID-19 rapid tests. Altai argues that a sale could value OraSure between $4.54 and $6.60 per share, representing a premium of 42% to 109% over its current market price. OraSure reported a 29% year-over-year revenue drop in its fourth quarter.

Economic and Market Impact

The activist pressure has influenced OraSure's stock performance. Shares initially rose around 18% when Altai nominated directors in January but recently closed at $2.98. OraSure's board responded by stating it is executing a strategy for long-term value and has made multiple settlement offers to Altai. The company aims for U.S. regulatory clearance for new products by 2026.

Summary

The situation remains tense as Altai Capital threatens a proxy fight if its demands are not met. The conflict places OraSure at a strategic crossroads, with its future direction dependent on whether it pursues a sale or continues with its current management's turnaround plan. Investors will be closely watching the board's next moves.

FAQ

Q: Why is Altai Capital targeting OraSure?
A: Due to significant underperformance, including a 73% stock price decline over five years, and a belief that a sale would generate substantial shareholder value.

Q: What is OraSure's estimated value in a potential sale?
A: Altai Capital estimates a sale could value the company at $4.54 to $6.60 per share.

Source: Investing.com